MTHFR and Pregnancy: Folate, Miscarriage Risk, and Prenatal Care

MTHFR (methylenetetrahydrofolate reductase) is an enzyme in the folate pathway, and its C677T and A1298C variants are among the most-searched results in consumer DNA data. The single most important thing to know about them in pregnancy is also the least intuitive: an MTHFR variant is not a reason to avoid folic acid. For preventing neural tube defects, folic acid is the only form of folate with randomized trial evidence behind it, and the CDC recommendation — 400 mcg daily for anyone who could become pregnant — does not change with your genotype.

Check your own MTHFR before you plan: find your C677T and A1298C variants in your 23andMe or AncestryDNA raw data, or upload your file to AskMyDNA and ask what your genotype means for folate choice — your first question is free, no credit card.

This guide covers what MTHFR variants do and do not change, what the trial evidence shows about neural tube defects and miscarriage, when testing is worth doing, and where methylfolate legitimately fits — which is not as a replacement for folic acid in pregnancy.

From the peer-reviewed literature

"Folic acid, alone or in combination with vitamins and minerals, prevents NTDs, but does not have a clear effect on other birth defects."

— De-Regil LM et al. Effects and safety of periconceptional oral folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2015. doi:10.1002/14651858.CD007950.pub3

What MTHFR Is — and What It Does Not Do

The Enzyme and Where It Actually Sits in the Pathway

MTHFR catalyzes one specific step in one-carbon metabolism: it converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF), the main circulating form of folate. That 5-MTHF then donates a methyl group to homocysteine, regenerating methionine.

The step that most MTHFR content gets wrong is the one before it. Folic acid — the synthetic form in supplements and fortified flour — is not processed by MTHFR at all. It is reduced to tetrahydrofolate by a different enzyme, dihydrofolate reductase (DHFR), before it ever reaches the MTHFR step. As the NIH Office of Dietary Supplements puts it, "before entering the bloodstream, the enzyme dihydrofolate reductase reduces the monoglutamate form to THF."

This matters because it dismantles the usual argument. The claim "your MTHFR is impaired, so you can't process folic acid" describes a step MTHFR does not perform. And dietary folate from food passes through the same MTHFR step that supplemental folate does — so a variant cannot single out folic acid as uniquely problematic. Whatever an MTHFR variant does, it does downstream of, and indifferent to, which folate form you started with.

Common Variants: C677T and A1298C

Two variants dominate consumer testing: C677T (rs1801133) and A1298C (rs1801131).

C677T is the better-characterized of the two. The TT genotype produces a thermolabile enzyme with reduced activity in laboratory assays. Population frequency varies substantially by ancestry — per the NIH Office of Dietary Supplements, roughly 25% of Hispanic, 10% of white and Asian, and 1% of Black individuals are homozygous for 677C>T.

A1298C has a milder biochemical effect. The CDC's position is explicit: "There isn't enough evidence to show that the MTHFR A1298C variant alone significantly affects how the body processes folate."

Compound heterozygosity (one copy of each) sits between the two single-variant states.

The Gap Between Enzyme Assays and Blood Folate

Reduced activity in a test tube is not the same as a folate deficit in a person, and the size of the real-world gap is where most MTHFR advice loses the thread. According to the CDC, when getting the same amount of folic acid, people with the 677 TT genotype have average blood folate levels only about 16% lower than people with the CC genotype.

A 16% difference in blood folate is a real biochemical finding. It is not the near-total metabolic block that "MTHFR mutation" content typically implies, and it does not support switching folate forms during pregnancy.

There is also direct trial evidence that folic acid works in exactly the genotype it is supposedly wrong for. In a randomized trial of two folic acid doses in 480 hypertensive Chinese adults, homocysteine fell across all genotypes, and TT subjects showed a greater homocysteine-lowering response than CC subjects in the higher-dose (0.8 mg) group — a mean reduction at week 8 of 22.0% in TT versus 10.8% in CC (P = 0.005). Two caveats keep this honest: absolute homocysteine remained higher in TT subjects than in CC even after treatment, and the trial studied a hypertensive population rather than pregnancy. But the direction is unambiguous. At an adequate dose, folic acid does not fail in TT individuals; it works at least as well as in wild-type.

Folate and Pregnancy: What the Trials Actually Show

Neural Tube Defects: Folic Acid, and Only Folic Acid

Neural tube defects — spina bifida and anencephaly — occur when the neural tube fails to close, between roughly days 21 and 28 after conception, usually before a pregnancy is confirmed. This is the outcome that periconceptional folate supplementation exists to prevent, and it is the best-evidenced intervention in prenatal nutrition.

The Cochrane review of periconceptional folate supplementation pooled five randomized trials covering 7,391 women. Daily folic acid supplementation reduced neural tube defects with a risk ratio of 0.31 (95% CI 0.17 to 0.58), rated high-quality evidence. The protective effect held for recurrence (RR 0.34, 95% CI 0.18 to 0.64) and was not affected by dose above the 400 mcg threshold, nor by whether folic acid was given alone or with other vitamins and minerals.

There were no trials of methylfolate on this endpoint. Not trials that failed, not trials with mixed results — none. The evidence base for preventing neural tube defects consists entirely of folic acid. The CDC states the same conclusion directly: "Folic acid is the only type of folate shown to help prevent neural tube defects."

This is why the recommendation does not bend around genotype. The CDC is unambiguous: "If you could become pregnant, you should get 400 mcg of folic acid daily, even if you have an MTHFR variant," and "Common MTHFR variants, such as MTHFR C677T, are not a reason to avoid folic acid." ACOG likewise recommends 400 to 800 mcg of folic acid daily before conception and in early pregnancy.

Women with a prior NTD-affected pregnancy are a separate case and are typically advised a much higher folic acid dose — this is a decision for your obstetrician, not a self-directed one.

Miscarriage: What the Same Review Found

Because this article's topic includes miscarriage risk, the honest finding deserves its own line. The same Cochrane review that established folic acid's protective effect against neural tube defects examined miscarriage across all five trials, 7,391 pregnancies, and found no effect: RR 1.10, 95% CI 0.94 to 1.28, moderate-quality evidence.

Folate supplementation prevents neural tube defects. It does not prevent miscarriage. Any recommendation that promises otherwise — including one framed around your MTHFR genotype — is going beyond the trial evidence.

The observational literature linking MTHFR variants to recurrent pregnancy loss is genuinely mixed. Some case-control studies report an association, particularly in women with elevated homocysteine; others find the effect attenuates or disappears after adjusting for maternal age and prior losses. UT Southwestern Medical Center summarizes the mainstream reading bluntly: "No peer-reviewed, validated research has associated MTHFR variants with pregnancy loss."

Homocysteine: A Marker, Not a Validated Target

Elevated homocysteine is the most measurable biochemical consequence of impaired folate metabolism, and it does correlate with placenta-mediated complications in observational work. But correlation with a marker is not the same as a treatment target.

The Cochrane review of homocysteine-lowering interventions pooled 15 randomized trials and 71,422 participants. B-vitamin supplementation reliably lowered homocysteine, but produced "no differences in effects of homocysteine-lowering interventions... on myocardial infarction, death from any cause or adverse events." A small favorable effect was found for stroke. Lowering the number did not deliver the outcomes the number is a proxy for.

For pregnancy, the practical implication is restraint: laboratory reference ranges generally sit below about 15 μmol/L, and a threshold of 10 is a convention rather than an outcome-validated target. Aggressive numerical homocysteine goals during pregnancy are not evidence-based, and chasing them with escalating supplement doses is not a validated strategy.

MTHFR Genetic Testing: Should You Test?

Who Should Consider Testing?

Mainstream obstetrics does not recommend routine MTHFR screening, and understanding why makes the remaining use cases clearer: testing is only worth doing when the result would change something.

Situations where testing may be discussed with a specialist:

• Recurrent pregnancy loss (three or more consecutive losses) after a standard workup — karyotyping, antiphospholipid antibodies, thyroid function — has come back normal
• Documented elevated homocysteine, where the goal is investigating the cause rather than the genotype itself
• A personal or family history that your obstetrician or maternal-fetal medicine specialist judges relevant

Situations where testing does not help:

• General preconception screening — ACOG does not recommend universal screening
• A single miscarriage, most of which are chromosomal
• Reassurance-seeking without a specific risk factor, since the folic acid recommendation is the same either way

Testing Options: Clinical vs. Consumer Tests

Clinical CLIA-certified laboratory tests are ordered through a physician, specifically report C677T (rs1801133) and A1298C (rs1801131), typically cost $100-300 without insurance, and come with medical interpretation.

Direct-to-consumer DNA tests (23andMe, AncestryDNA, MyHeritage) include both variants in their raw data files. The genotyping itself is reliable; the interpretation layer is where consumer MTHFR content most often goes wrong, since much of it is built on the folic-acid-avoidance premise this article is correcting.

Interpreting Your MTHFR Results

Your report will show a genotype at each position. Here is what each one does — and does not — change about prenatal care:

The consistent entry in that last column is the point. No MTHFR genotype currently changes the recommended folate form or the baseline dose for preventing neural tube defects.

What genotype does not tell you, and what actually varies between people, is functional status: your measured homocysteine, your B12 status, your dietary intake, and other thrombophilia variants such as Factor V Leiden and prothrombin G20210A, which carry their own separate clinical significance.

When Testing Is NOT Recommended

ACOG does not recommend MTHFR testing for routine prenatal screening, for women without prior pregnancy complications, as anxiety-driven screening, or after a single pregnancy loss. The reasoning is consistent throughout: the result does not change management. Standard prenatal care already includes the intervention that works.

Prenatal Supplementation: What To Actually Take

Folate: Form and Dose

For preventing neural tube defects, before conception and through early pregnancy:

• Folic acid, 400 to 800 mcg daily, regardless of MTHFR genotype. This is the CDC and ACOG recommendation and the form with randomized trial support.
• Start before conception. The neural tube closes by about week four, frequently before a pregnancy test is positive. Supplementation begun after a missed period has already missed the window it exists to protect.
• A standard prenatal vitamin meets this. There is no genotype-specific prenatal formulation with outcome evidence behind it, and no need to seek one out.

If you are already taking a prenatal vitamin containing methylfolate, that is not a cause for alarm — but if you are choosing, choose the form the trials tested.

Where Methylfolate Legitimately Fits

Methylfolate is not a fringe supplement, and this article is not an argument against it in general. Outside of pregnancy and NTD prevention, it has a real place. The NIH Office of Dietary Supplements notes that "for some people, supplementation with 5-MTHF might be more beneficial than with folic acid" — for instance when folic acid has not normalized homocysteine, or where tolerability is the deciding factor.

The distinction is about which claim is being made:

What the evidence does not support at any dose or genotype is substituting methylfolate for folic acid to prevent neural tube defects.

B-Vitamin Cofactors

Folate metabolism depends on several cofactors, and adequate intake of them is uncontroversial. A standard prenatal vitamin covers these; the table is for understanding what each does, not a prompt to add separate products.

B12 deserves specific attention for a reason unrelated to genotype: folate supplementation can mask the hematologic signs of B12 deficiency while neurological damage progresses. Adequate B12 matters for everyone taking folate, whatever their MTHFR status.

Dietary Folate

Food folate is worth eating on its own merits, though it is worth being precise about why: dietary folate does not bypass MTHFR. It passes through the same enzymatic step as any other folate. What it does is contribute to overall folate status alongside — not instead of — the supplement.

High-folate foods: leafy greens (spinach, kale, romaine), legumes (lentils, chickpeas, pinto beans), cruciferous vegetables (broccoli, Brussels sprouts), asparagus, beef liver, and eggs. Fortified grains contribute folic acid, which is the point of fortification programs and a substantial reason NTD rates fell after they were introduced.

Worth limiting in pregnancy: alcohol, which impairs folate absorption and metabolism, and smoking. Both matter considerably more than folate form.

MTHFR and Ask My DNA

Ask My DNA reads the MTHFR variants already present in the raw data file you upload from 23andMe, AncestryDNA, or a similar service, and tells you which genotype you carry in plain language — including, where relevant, that your genotype does not change the folic acid recommendation.

That last part is the useful output. Most MTHFR interpretation available online is built on the premise that a variant demands a change in supplement form; a genotype readout that tells you when the answer is "this changes nothing" is more actionable than one that manufactures a protocol. For anything touching an actual pregnancy plan, the interpretation belongs in a conversation with your obstetrician.

FAQ

Q1: Should I test for MTHFR while pregnant or trying to conceive?

For most people, no. ACOG does not recommend routine MTHFR screening, primarily because the result does not change management — the folic acid recommendation is 400 to 800 mcg daily either way. Testing may be worth discussing with a maternal-fetal medicine specialist after recurrent pregnancy loss with an otherwise normal workup. If you have already tested through a consumer service and found a variant, the correct response is not to change your folate form.

Q2: Can MTHFR variants cause pregnancy complications?

The observational literature is mixed and the mainstream position is skeptical. Some case-control studies report associations with pregnancy complications, particularly alongside elevated homocysteine; larger and better-controlled studies frequently find the effect attenuates after adjustment for maternal age and prior losses. UT Southwestern states that no peer-reviewed, validated research has associated MTHFR variants with pregnancy loss. Carrying a variant is common and most carriers have uncomplicated pregnancies.

Q3: What is the relationship between MTHFR and miscarriage?

Weaker than most online content implies. The Cochrane review of periconceptional folate found no effect on miscarriage across five trials and 7,391 pregnancies (RR 1.10, 95% CI 0.94 to 1.28). Studies linking MTHFR specifically to recurrent loss are observational and inconsistent. For recurrent pregnancy loss, a full evaluation for established causes — including antiphospholipid syndrome, uterine anatomy, and chromosomal factors — matters considerably more than MTHFR status.

Q4: Do I need special prenatal vitamins if I have MTHFR?

No. A standard prenatal vitamin containing 400 to 800 mcg of folic acid is what the evidence supports, whatever your genotype. The CDC states directly that people with an MTHFR gene variant can process all types of folate, including folic acid, and that common variants are not a reason to avoid it. Methylfolate-based prenatals are not harmful, but they are not superior for preventing neural tube defects, and no trial has tested them for that.

Q5: What is the difference between methylfolate and folic acid?

Folic acid is the synthetic form used in supplements and fortification. It is reduced by DHFR — not MTHFR — and then proceeds through the folate cycle. Methylfolate (L-5-MTHF) is the already-methylated form that enters the cycle further along. Both end up as usable folate. The practical difference for pregnancy is evidentiary rather than biochemical: folic acid is the form with randomized trial evidence for preventing neural tube defects, and methylfolate has none on that endpoint.

Q6: If I have the TT genotype, shouldn't I at least take more folate?

The trial evidence does not support escalating dose by genotype. Cochrane found the protective effect against neural tube defects was not affected by dose above 400 mcg. People with the TT genotype have average blood folate about 16% lower than CC at the same intake — a real but modest difference — and in randomized dosing, TT individuals showed a greater homocysteine-lowering response to folic acid than CC individuals. If you have a specific reason to consider a higher dose, such as a prior NTD-affected pregnancy, that is a conversation with your obstetrician.

Q7: How accurate is MTHFR genetic testing?

The genotyping itself is highly accurate at CLIA-certified laboratories and reliable in consumer raw data. Accuracy is not the weak link — interpretation is. A correct genotype paired with the claim that you should avoid folic acid produces a worse outcome than not testing at all.

Q8: Can MTHFR variants be inherited from both parents?

Yes. You can inherit two copies of the same variant (homozygous, such as C677T TT) or one of each (compound heterozygous). These variants are common enough that inheriting them is unremarkable — in some populations, most people carry at least one copy of C677T.

Q9: What is homocysteine and does it matter in pregnancy?

Homocysteine is an amino acid that accumulates when the folate and B12 pathways are impaired, and it correlates with placenta-mediated complications in observational studies. But it is a marker rather than a validated treatment target: across 15 randomized trials and 71,422 participants, lowering homocysteine with B vitamins did not reduce myocardial infarction or all-cause mortality, with only a small favorable effect on stroke. Laboratory reference ranges generally sit below about 15 μmol/L; tighter numerical goals are conventions, not outcome-validated targets.

Q10: Are there risks to taking extra methylfolate during pregnancy?

The more relevant question is what it displaces. Methylfolate at typical supplement doses has no documented harm, but if taken instead of folic acid, you have substituted a form with no trial evidence for neural tube defect prevention for the one form that has it. That is the real risk, and it is not a risk of toxicity.

Q11: How does MTHFR interact with other genetic variants?

The variants that matter clinically for pregnancy thrombosis risk are the established thrombophilias — Factor V Leiden and prothrombin G20210A — which have their own evidence base and management guidance independent of MTHFR. If you have a personal or family history of venous thromboembolism or severe placental complications, that history warrants proper thrombophilia evaluation, which is a broader question than MTHFR.

Q12: When should I start folic acid — before or during pregnancy?

Before. The neural tube closes by about four weeks after conception, often before a positive pregnancy test, so supplementation started after a missed period has already missed the critical window. The CDC recommendation applies to anyone who could become pregnant, not only those actively trying — roughly half of pregnancies are unplanned, which is the reasoning behind the population-wide advice and behind mandatory folic acid fortification of grain products.

Conclusion

MTHFR is a real gene with real variants, and they are genuinely common. What they are not is a reason to change your folate form during pregnancy.

The evidence points one way and it is not close. Folic acid prevents neural tube defects across five randomized trials and 7,391 women. Methylfolate has never been tested on that endpoint. Folic acid works in people with the TT genotype — at an adequate dose, better than in wild-type. The blood folate gap between TT and CC at equal intake is about 16%, not a metabolic block. And folic acid is reduced by DHFR, an enzyme MTHFR variants do not touch.

If you carry an MTHFR variant and are planning a pregnancy: take 400 to 800 mcg of folic acid daily, start before conception, and treat your genotype as interesting rather than actionable. If you have a history of recurrent pregnancy loss, a prior NTD-affected pregnancy, or documented elevated homocysteine, those histories deserve a real workup with your obstetrician — one in which MTHFR is a minor consideration rather than the headline.

📋 Educational Content Disclaimer

This article provides educational information about genetic variants and is not intended as medical advice. Always consult qualified healthcare providers for personalized medical guidance. Genetic information should be interpreted alongside medical history and professional assessment.